Vanessa Gómez Vallejo
Our current research is focused in the development and evaluation of novel diagnostic, therapeutic and theranostic agents using a combination of in vivo and minimally invasive molecular imaging techniques such as positron emission tomography (PET) and single photon emission computerized tomography (SPECT). Strategies for the radiolabelling of new chemical entities, including small molecules, peptides, proteins, antibodies (or fragments) and nanomaterials are continuously pursuit, followed by in vivo evaluation to asses pharmacokinetic properties (mainly biodistribution and metabolism) and specific or preferential uptake in target organs or tissues in order to predict potential therapeutic efficacy and side effects. Recent works include, among others: (i) development of nanoparticule-based therapeutic agents for the treatment of pancreatic adenocarcinoma; (ii) design and synthesis of radiotracers for the early detection of AD in mouse models; and (iii) evaluation of multi-labelled drug nanocarriers for the treatment of antibiotic-resistant lung infectious diseases. Access to a wide variety of in-house produced (64Cu, 89Zr, 68Ga) and commercially available (67Ga, 111In, 99mTc) radiometals, together with the tracked experience of our research group in the areas of radiochemistry and molecular imaging, guarantee a significant added value to this consortium and open new avenues for the future in vivo evaluation of drug candidates developed by other members participating in this project.
Research group member:
You can contact us at:
7 March 2017: Conchita Gimeno is one of the awardees of the IUPAC 2017 Distinguished Women in Chemistry
20 October 2016: Second MetDrugs meeting
2 February 2016: First MetDrugs meeting
14 october 2015: The Ministry of Economy and Competitiveness of Spain finances the network